Global Immunotherapy Drugs Market Outlook 2030

The global cancer immunotherapy market is likely to attain revenue of ~USD 120 billion in 2021 and is projected to mark a CAGR of 15% between 2022 and 2030. Increasing adoption of advanced cancer treatment options, coupled with an increase in cancer incidence, has been one of the main drivers of market growth. Healthcare providers are working to improve cancer treatment facilities and reduce the recurrence rate of tumors after chemotherapy.

The increasing R&D activities in the field of cancer immunotherapy have led to the introduction of advanced variants with higher therapeutic effects and effectiveness. Immuno-oncology has shown promising results with better survival rates and lower toxicity. The paradigm shift from traditional chemotherapy to immunotherapy is driving the development of the entire market.

Compared with existing therapies, immunotherapies under development may provide more treatment options and better results. The launch of new drugs such as monoclonal antibodies against multiple myeloma-related receptors and histone deacetylase (HDAC) inhibitors is expected to shape the future of the market. Ongoing research on similar drugs aimed at minimizing side effects is expected to stimulate market growth.

In addition, checkpoint inhibitors PD-1 and CTLA-4 were approved for the treatment of melanoma and non-small cell lung cancer (NSCLC), driving market growth. Approvals for innovative forms of immunotherapeutic drugs (such as vaccines and adjuvants) are increasing. In addition, more immunotherapies are being tested to improve results, such as immunomodulators and CAR T cell therapies. These new approvals and ongoing investigations are expected to stimulate market growth during the forecast period.

PRODUCT INFORMATION:

Monoclonal antibody (mAb) is the most prominent product area in 2018. Increasing investment in monoclonal antibodies, such as naked antigen-binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies, has opened up new revenue-generating avenues for companies that provide cancer treatments. These R&D activities have led to the introduction of adaptive immunity, Antigen-specific and antibody-dependent cytotoxicity and other effects of mAb. Because of the various benefits of mAbs, they are being studied for the treatment of various types of tumors.

Unlike other chemotherapy drugs, immunomodulators are used to regulate the patients immune system, thereby enhancing the immune systems activity against tumors. Immunomodulators such as cytokine modulators and growth factors are non-specific therapies. These non-specific therapies are designed to act as immune stimulants and thereby produce better responses to tumor cells.

The efficacy and accuracy of these immunomodulatory drugs continue to improve, leading to an increase in market penetration. In addition to these approved drugs, market participants are working hard to introduce several new therapies.

CANCER TYPE INFORMATION:

By type, the global cancer immunotherapy market has been subdivided into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, ovarian cancer and pancreatic cancer. Most immunotherapy drugs, including some monoclonal antibodies and checkpoint inhibitors, are approved for the treatment of non-small cell lung cancer. Monoclonal antibodies successfully prevent tumor cells from forming new blood vessels and promote alternative ways to inhibit tumor cell growth.

Checkpoint inhibitors are used as first-line treatment for patients with advanced lung tumors. Opdivo, Keytruda and Tecentriq are approved as immunotherapeutic drugs for the treatment of lung tumors. These drugs are usually used in the case of tumor recurrence after chemotherapy. The aforementioned factors are believed to have driven the adoption of these drugs.

Cancer immunotherapy is increasingly used in the treatment of melanoma. The growth of the melanoma segment can be attributed to the development of new products, numerous FDA approvals, and extensive research and development in this area. The US FDA recently approved three checkpoint inhibitors for the treatment of melanoma, three cytokine therapies, and one oncolytic virus therapy. Keytruda, Yervoy, and Opdivo are commercially available checkpoint inhibitors that stimulate the patients immune response to melanoma cells, thereby shrinking tumors and extending the life expectancy of patients with advanced melanoma.

REGIONAL INFORMATION:

North America had the highest revenue share in 2018. The incidence of the disease is rising, modern treatments are becoming more and more accessible, coupled with the expansion of the elderly population, is promoting the growth of the regional market. The Asia-Pacific region is expected to experience the fastest growth. During the forecast period. China and Japan are introducing new and advanced immunotherapy drugs. There are several ongoing clinical trials in these countries, as well as FDA approval of new drug molecules and combination therapies. The approval of new therapeutic drugs in China and Japan is promoting the use of immunotherapy to treat tumors. In addition, there is a lack of regulatory and cultural constraints, as well as the presence of market participants with large investments in the market, such as AstraZeneca; Merck; and Pfizer are expanding the Asia-Pacific market.

MAJOR COMPANIES AND MARKET SHARE PROSPECTS:

The market is highly competitive. Major participants include Amgen; AstraZeneca; F. Hoffman La Roche; Bayer AG; Bristol-Myers Squibb; Eli Lilly and Company; Merck & Co; Novartis; and Pfizer. The key parameters affecting the nature of competition are the rapid adoption of advanced treatment options to improve healthcare, and the growing demand for optimal capital utilization. In addition, in order to maintain participation and diversify product portfolios, major players often adopt merger and acquisition strategies.

MARKET SEGMENTS COVERED BY THE REPORT:

This report forecasts global, regional, and national revenue growth, and analyzes industry trends in each sub-segment from 2021 to 2030. For the purpose of this research, Kenneth Research has conducted a segmentation of global cancers. Immunotherapy market report based on product, cancer type and region: Product outlook (revenue, billions of dollars, 2021 to 2030) Monoclonal antibody immunomodulator Unolytic Viral Therapy and Vaccine Cancer Type Outlook (Revenue, Billion USD, 2021 to 2030) Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer.

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

• North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.